US Patent

US8501712 — Boron-containing small molecules as anti-inflammatory agents

Method of Use · Assigned to Anacor Pharmaceuticals LLC · Expires 2027-02-16 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses methods of treating anti-inflammatory conditions using boron-containing small molecules.

USPTO Abstract

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

Drugs covered by this patent

Eucrisa (Crisaborole) · Anacor Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1932`	—	Eucrisa

Patent Metadata

Patent number: US8501712
Jurisdiction: US
Classification: Method of Use
Expires: 2027-02-16
Drug substance claim: No
Drug product claim: No
Assignee: Anacor Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.